Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Additive diagnostic value of prostate specific membrane antigen (PSMA) positron emission tomography (PET) to multiparametric magnetic resonance imaging (mpMRI) in the diagnostic setting: Ability to reduce unnecessary prostate biopsies in men being investigated for prostate cancer.

Next Previous
Trial Profile

Additive diagnostic value of prostate specific membrane antigen (PSMA) positron emission tomography (PET) to multiparametric magnetic resonance imaging (mpMRI) in the diagnostic setting: Ability to reduce unnecessary prostate biopsies in men being investigated for prostate cancer.

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Nov 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs 68-Ga-PSMA-617 (Primary)
  • Indications Prostate cancer
  • Focus Diagnostic use
  • Acronyms PRIMARY

    • Most Recent Events

    • 13 Nov 2022 Results of retrospective analysis (n=100) to identify synchronous reading of multiparametric MRI (mpMRI) and 68Ga-PSMA-11 PET/CT (PSMA-PET) images can improve diagnostic performance and certainty against mpMRI/PSMA-PET reported independently and synthesized, while also assessing concordance between imaging modalities and agreement with histopathology from the PRIMARY trial, published in the BJU International.
    • 18 Jul 2019 Planned initiation date changed from 29 Oct 2018 to 19 Jul 2019.
    • 18 Jul 2019 Planned End Date changed from 15 Apr 2019 to 30 Jun 2020.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top